IAMOG
MYGN icon

Investors Asset Management of Georgia’s Myriad Genetics MYGN Stock Holding History

Investors Asset Management of Georgia’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-202
Closed -$4K – 395
2022
Q3 		$4K Hold
202
– – ﹤0.01% 548
2022
Q2 		$4K Buy
+202
New +$4.19K ﹤0.01% 497

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Investors Asset Management of Georgia's MYGN Position: Q4 2022 in Review

Investors Asset Management of Georgia sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 202 shares — an estimated $4K sold.

Investors Asset Management of Georgia first reported a position in MYGN in Q2 2022 and held it in 2 quarters. The position peaked at $4K in Q3 2022. 195 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

  • Investors Asset Management of Georgia reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 202 Myriad Genetics shares in Q4 2022, an estimated $4K.
  • Investors Asset Management of Georgia first reported a position in Myriad Genetics in Q2 2022 and held it in 2 quarters.
  • Investors Asset Management of Georgia's Myriad Genetics position peaked at $4K in Q3 2022.
  • 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on Investors Asset Management of Georgia's 13F filing for Q4 2022, filed 2 Feb 2023.